OnKure Therapeutics
OKUR
33 hedge funds and large institutions have $55.1M invested in OnKure Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 4 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more capital invested
Capital invested by funds: $43.3M → $55.1M (+$11.8M)
0.03% more ownership
Funds ownership: 6.7% → 6.72% (+0.03%)
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$208K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$115K |
| 3 |
JP Morgan Chase
New York
|
+$86.6K |
| 4 |
Renaissance Technologies
New York
|
+$65.7K |
| 5 |
Morgan Stanley
New York
|
+$63.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$97.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$86.8K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$82.1K |
| 4 |
Millennium Management
New York
|
-$73.1K |
| 5 |
NM
Newtyn Management
New York
|
-$56K |
OKUR Hedge Fund Activity: Q3 2022 in Review
33 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2022, worth a combined $55.1M — up 27% from $43.3M a quarter earlier.
Fund positioning in OKUR was balanced in Q3 2022: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 8 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $208K. The largest seller was Ikarian Capital, cutting an estimated $97.8K.
- 33 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $55.1M of OnKure Therapeutics stock for Q3 2022, up 27% quarter-over-quarter.
- 4 funds opened new OnKure Therapeutics positions in Q3 2022 and 4 closed out, a net change of 0 holders.
- The largest OnKure Therapeutics buyer in Q3 2022 was MAI Capital Management, an estimated $208K added.
- The largest OnKure Therapeutics seller in Q3 2022 was Ikarian Capital, an estimated $97.8K sold.
Based on aggregated 13F filings for Q3 2022.